AOD-9604
HGH Fragment 176-191
AOD-9604 (HGH Fragment 176-191) is a metabolic & fat loss research compound. Modified C-terminal fragment of GH — stimulates lipolysis and inhibits lipogenesis without hitting IGF-1 or blood sugar.
AOD-9604 quick facts
| Reported research dosing | 250mcg-500mcg |
| Route | Subq |
| Cycle length | 8-12 Weeks |
| Frequency | 1x Daily AM · 5 On 2 Off or Daily |
| Half-life | ~30 min |
| Forms | Injectable, Nasal |
| Evidence level | Animal + limited human (modest) |
Fat-loss lever without the GH/IGF baggage. Manage expectations — it's a nudge, not magic.
How AOD-9604 works
Modified C-terminal fragment of GH — stimulates lipolysis and inhibits lipogenesis without hitting IGF-1 or blood sugar.
Proposed benefits
Lipolysis / fat loss without GH- or blood-sugar-related side effects.
✅ Clinically validated
- Human trials exist, and reading them properly matters more here than almost anywhere in the Vault. A phase 2b obesity trial run by Metabolic Pharmaceuticals enrolled several hundred participants and missed its primary endpoint: total body-weight loss was not significantly better than placebo.
- That result is routinely misread as 'it does nothing'. The endpoint was scale weight. AOD-9604 is a lipolytic fragment with the growth-promoting and appetite-affecting regions deliberately removed — it was never going to suppress intake, and a compound that mobilises fat without changing what you eat will not move a scale in twelve weeks against placebo. Earlier phase-2 work did report reductions in body fat and improvements in lipid handling.
- It was subsequently granted GRAS status as a food ingredient in the US. That is a statement about safety, not efficacy — but it is also why this is one of the most benign things in the fat-loss category.
📊 Correlative data
- Still widely used for fat loss, largely on the strength of the mechanism and the excellent safety record rather than the trial result. Reported experience is mild, which is consistent with what the trial found.
🧪 Theoretical / extrapolated
- The C-terminal fragment (176–191) of human growth hormone — the region associated with lipolytic activity, with the growth-promoting and glucose-antagonising regions removed. That separation is the design goal and it works: it does not raise IGF-1 or affect blood glucose.
- Rodent work shows stimulated lipolysis and inhibited lipogenesis. The honest reading is that the mechanism is real and the effect size in humans is small — which the phase 2b result already told us.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
AOD-9604 — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- Everything here follows from one fact: these raise GH and therefore IGF-1. The predicted problems are the known consequences of elevated GH/IGF-1, drawn from acromegaly and clinical GH therapy where it HAS been studied — insulin resistance and rising fasting glucose, fluid retention (puffy hands and face, and the ring that stops fitting), carpal tunnel symptoms from that same fluid pressing on the median nerve, and joint aches.
- The proliferation question is the serious one. IGF-1 is a growth signal, and growth signals do not distinguish between tissue you want to grow and tissue you do not. There is no evidence these compounds cause cancer. There is also a clear mechanistic reason not to run them with an active or recent malignancy, and that reasoning does not require a trial to be sound.
What has actually been reported
- Injection-site reactions, transient flushing, tingling and head-rush on dosing — most commonly with the GHRPs, which also release cortisol and prolactin at higher doses.
- Increased hunger is near-universal with the ghrelin-mimetic ones (GHRP-6, MK-677, Hexarelin). That is the mechanism working, not a side effect — the same receptor drives GH release and appetite.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Draw an IGF-1 baseline BEFORE you start. Once you are on, that number is the drug and you have permanently lost the comparison. This is the single highest-value thing on this list and it costs one blood draw.
- Watch fasting glucose and HbA1c, not the scale. Insulin resistance is the most likely thing to move and the one you cannot feel. Re-test at 8–12 weeks. If fasting glucose is climbing, that is your signal to cut the dose or come off — long before anything shows up symptomatically.
- Dose at night, on an empty stomach. GH release is pulsatile and largest during early sleep; food, and carbohydrate in particular, blunts the pulse through insulin. This is not a ritual — it is the same mechanism working with you rather than against you.
- Don't run a secretagogue through a high-carbohydrate surplus. The predicted problem is insulin resistance; adding a large carb load is pushing the same lever from the other end.
- Cycle rather than run continuously. Most of the predicted problems — fluid retention, carpal tunnel, glucose drift — are dose-and-duration dependent and reverse on cessation. Time off is the cheapest safety intervention available.
- If fluid retention is the issue, it usually resolves on a dose reduction long before it needs anything else. Reach for the dose before you reach for a diuretic.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- IGF-1 drawn on-cycle is not your baseline — it is the drug working, and it will read high. If you want a real baseline, draw before starting or after a proper washout.
- Watch fasting glucose and HbA1c, because insulin resistance is the most likely thing to move and the one you will not feel.
- GHRP-6 and Hexarelin can raise prolactin and cortisol; if you are chasing an unexplained prolactin result, this is a candidate.
What it overlaps with
- Stacking two secretagogues that work by the same route is redundancy, not synergy. A GHRH analogue (CJC-1295, Sermorelin, Tesamorelin) plus a ghrelin mimetic (Ipamorelin, GHRP-2, GHRP-6) is the deliberate pairing — two different levers on the same axis. Two GHRH analogues together is paying twice for one lever.
Don't run this if
- Active or recent malignancy — the IGF-1 reasoning above.
- Diabetes or poor glycaemic control, unless you are monitoring fasting glucose and HbA1c and know what you are looking at.
- Untreated diabetic retinopathy.
The honest unknown
- Nobody has run long-term studies of intermittent secretagogue use in healthy adults. The specific unmeasured thing is what years of repeatedly pushing IGF-1 above your natural set point does — not whether a single cycle is tolerable, which it evidently is.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Close to the tissue, and consistency beats the clock — fasted
A brief exposure starts a process that runs for days, so the hour you dose is a minor variable — missing days is the one that costs you. Where the target is local, dosing near the site is worth more than any timing choice.
The fasted flag on this one is real: food blunts absorption enough to matter.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
AOD-9604 reconstitution calculator
Research reconstitution calculator
Where to get AOD-9604
Buy AOD-9604 at AminoWell USA →AOD-9604 — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What AOD-9604 moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for AOD-9604 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
Bloodwork to run alongside AOD-9604
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 102 markers A–Z
AOD-9604 — frequently asked questions
What is AOD-9604?
AOD-9604 (HGH Fragment 176-191) is a metabolic & fat loss research compound. Modified C-terminal fragment of GH — stimulates lipolysis and inhibits lipogenesis without hitting IGF-1 or blood sugar.
What dosing does the research reference for AOD-9604?
In the research literature, AOD-9604 is referenced in the 250mcg-500mcg range, 1x Daily AM · 5 On 2 Off or Daily. It is supplied as a lyophilized powder and reconstituted with bacteriostatic water; the calculator above converts a research amount into syringe units. For research use only — not a recommendation for human use.
What is the half-life of AOD-9604?
AOD-9604 has an approximate half-life of ~30 min, which is part of what determines how often it's dosed.
What forms does AOD-9604 come in?
AOD-9604 is available as: Injectable, Nasal.
What's the evidence behind AOD-9604?
Current evidence level: Animal + limited human (modest). AOD-9604 is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact AOD-9604 protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What AOD-9604 is used for
AOD-9604 appears under 1 goal in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.